First Trust Advisors LP Acquires 111,163 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

First Trust Advisors LP raised its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 508.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 133,038 shares of the company's stock after purchasing an additional 111,163 shares during the period. First Trust Advisors LP's holdings in Elanco Animal Health were worth $1,611,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health during the third quarter worth $35,000. Jones Financial Companies Lllp lifted its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. lifted its position in shares of Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after acquiring an additional 3,411 shares in the last quarter. MRP Capital Investments LLC purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth $61,000. Finally, Blue Trust Inc. lifted its position in shares of Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Price Performance

NYSE ELAN traded up $0.66 during trading hours on Monday, reaching $12.62. 638,578 shares of the stock traded hands, compared to its average volume of 4,971,791. The stock has a 50 day simple moving average of $9.89 and a two-hundred day simple moving average of $11.42. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market cap of $6.27 billion, a price-to-earnings ratio of 31.67, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the business posted $0.34 earnings per share. The company's revenue for the quarter was down 1.0% on a year-over-year basis. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ELAN shares. Stifel Nicolaus increased their target price on Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday. Piper Sandler dropped their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. UBS Group lowered their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley lowered their price objective on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Finally, Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $15.00.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average cost of $10.90 per share, with a total value of $109,000.00. Following the completion of the purchase, the director now directly owns 101,459 shares of the company's stock, valued at $1,105,903.10. This trade represents a 10.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.89% of the company's stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.